文献速递中医内科中药与中成药合理使用

黄芪桂枝五物汤预防奥沙利铂神经毒性:12中心随机双盲试验

Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation.
PubMed 文献 · Phytomedicine · 2026-07-01

本研究为多中心、随机、双盲、安慰剂对照试验,在12家三级医院纳入360例拟行XELOX化疗的结直肠癌成人患者,评估黄芪桂枝五物汤预防奥沙利铂所致周围神经病变(OIPN)的疗效与安全性。结果显示,治疗组≥2级慢性OIPN发生率为21.3%,安慰剂组为38.6%(OR 0.43,95%CI 0.27-0.69,P<0.001),不良事件两组相当。动物与临床血清学机制验证提示该方可能通过减轻氧化应激与炎症发挥神经保护作用。

要点

  • 黄芪桂枝五物汤可降低XELOX化疗患者≥2级慢性OIPN发生率。
  • 不良事件与安慰剂相当,未增加毒性。
  • 机制可能涉及降低IL-1β、MCP-1、MDA及提升SOD活性。

核心结论

  • 黄芪桂枝五物汤显著降低奥沙利铂所致周围神经病变发生率且不增加毒性。
  • 临床前与血清学结果提示其神经保护作用可能与减轻氧化应激和改善线粒体自噬有关。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照试验,在中国12家三级医院开展。
  • 纳入拟行XELOX化疗的结直肠癌成人患者,按1:1随机分配至口服黄芪桂枝五物汤颗粒或安慰剂(每袋47.5 g,每日两次),全程化疗期间服用。
  • 共入组360例,改良意向性治疗(mITT)分析纳入354例;主要终点为mITT人群中≥2级慢性OIPN发生率,采用logistic回归并多重插补处理缺失数据。

主要发现

  • 黄芪桂枝五物汤组≥2级慢性OIPN发生率为21.3%,安慰剂组为38.6%(OR 0.43;95%CI 0.27-0.69;P<0.001)。
  • 两组不良事件发生率相当(OR 1.27;95%CI 0.68-2.39;P=0.524)。
  • 动物模型中,黄芪桂枝五物汤提高痛阈、保护背根神经节、降低IL-1β、MCP-1和MDA水平并增强SOD活性。
  • 临床血清ELISA分析显示,该方减轻化疗引起的促炎细胞因子(IL-1β、MCP-1)和氧化应激标志物(MDA)升高,并保持抗氧化酶(SOD)活性。

关键数值与推荐

  • 主要疗效指标:≥2级慢性OIPN发生率,黄芪桂枝五物汤组21.3% vs 安慰剂组38.6%,OR 0.43(95%CI 0.27-0.69),P<0.001。
  • 安全性指标:不良事件OR 1.27(95%CI 0.68-2.39),P=0.524。
  • 干预方案:黄芪桂枝五物汤颗粒每袋47.5 g,每日两次口服,全程化疗期间使用。

临床怎么用

  • 对于接受XELOX化疗的结直肠癌患者,可考虑在化疗全程联用黄芪桂枝五物汤以预防OIPN。
  • 使用期间不良事件风险与安慰剂相当,但仍需按常规监测。
  • 该方可能通过抗炎与抗氧化途径发挥神经保护作用,可作为OIPN预防策略之一。

局限性

  • 原文未报告针对OIPN预防以外的其他化疗毒性终点。
  • 机制验证主要基于动物模型与血清标志物,临床硬终点证据仍需进一步积累。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oxaliplatin-induced peripheral neuropathy (OIPN) affects up to 80% of patients receiving oxaliplatin-based chemotherapy, and effective preventive strategies remain limited. Huangqi Guizhi Wuwu Decoction (HQGZWWD), a traditional Chinese herbal formula included in China's National Classic Famous Formulas, is widely used for OIPN in clinical practice, but high-quality clinical evidence remains lacking. PURPOSE: This study evaluated the efficacy and safety of HQGZWWD for OIPN prevention and explored its neuroprotective mechanisms. METHODS: We conducted a multicenter, randomized, double-blind, placebo-controlled trial at 12 tertiary hospitals in China. Adults with colorectal cancer scheduled to receive XELOX chemotherapy were randomly assigned (1:1) to oral HQGZWWD granules or placebo (47.5 g per sachet, twice daily) throughout chemotherapy. Participants, outcome assessors, and statisticians were blinded. The primary outcome was the incidence of grade ≥2 chronic OIPN in the modified intention-to-treat population, analyzed using logistic regression with multiple imputation for missing data. RESULTS: A total of 360 participants were enrolled, and 354 were included in the modified intention-to-treat analysis. Grade ≥2 chronic OIPN occurred in 21.3% of patients receiving HQGZWWD group and 38.6% in the placebo group (OR, 0.43; 95% CI, 0.27-0.69; P<0.001). Adverse events were comparable between groups (OR, 1.27; 95% CI, 0.68-2.39; P=0.524). In animal models, HQGZWWD increased pain thresholds, preserved dorsal root ganglia, reduced IL-1β, MCP-1, and MDA levels, and enhanced SOD activity. Consistently, clinical serum enzyme-linked immunosorbent assay (ELISA) analyses further validated these mechanisms, demonstrating that HQGZWWD significantly attenuated chemotherapy-induced elevations of pro-inflammatory cytokines (IL-1β, MCP-1) and oxidative stress marker (MDA), while preserving antioxidant enzyme (SOD) activity in CRC patients receiving XELOX chemotherapy. CONCLUSION: HQGZWWD significantly reduced the incidence of OIPN without increasing toxicity. Preclinical findings suggest that these effects may involve reduced oxidative stress and improved mitophagy. These findings support HQGZWWD as a promising preventive strategy for OIPN. TRIAL REGISTRATION: The trial is registered with ClinicalTrials.gov (NCT04913376).

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Sun X, Fang Y, Yang X, et al. Neuroprotection and prevention of oxaliplatin-induced neuropathy with Huangqi Guizhi Wuwu Decoction: a 12-center randomized, double-blind trial with mechanistic validation. Phytomedicine. 2026. PMID: 42435525. doi:10.1016/j.phymed.2026.158539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。